All stock lists
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
Healthcare · Biotechnology
4.77+0.36 (+8.18%)
Insider Score
––Not scored
TRDA Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
TRDA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 898.00 K | 875.00 K | 1.30 M | 1.61 M | 1.95 M |
| Revenue Growth (YoY) | -53.95 % | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| SG&A Expense | 10.49 M | 10.12 M | 9.55 M | 10.30 M | 10.92 M |
| R&D Expense | 35.37 M | 33.05 M | 33.96 M | 38.36 M | 37.88 M |
| Operating Expenses | 45.86 M | 43.18 M | 43.51 M | 48.66 M | 48.80 M |
| Operating Income | -44.96 M | -42.30 M | -42.21 M | -47.05 M | -46.85 M |
| Pretax Income | -42.73 M | -39.68 M | -39.07 M | -43.48 M | -42.92 M |
| Tax Provision | 35.00 K | 38.00 K | 92.00 K | 654.00 K | 178.00 K |
| Net Income | -42.76 M | -39.72 M | -39.16 M | -44.13 M | -43.10 M |
| EPS (Basic) | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
| EPS (Diluted) | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
| Shares Outstanding | 42.22 M | 41.84 M | 41.60 M | 41.46 M | 41.34 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.